Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Boston Life Sciences identifies a second antiangiogenic molecule

Feb. 8, 1999

Orphan Medical's Busulfex Injection approved in U.S.

Feb. 8, 1999

Lorus Therapeutics announces preclinical data on anticancer compound

Feb. 8, 1999

Aronex's NDA for Atragen accepted for review

Feb. 5, 1999

Vitaxin proceeds to phase II

Feb. 5, 1999

First phase I clinical trials commence with NX-211

Feb. 4, 1999

Preclinical study of TRAIL points to promise as antitumor agent

Feb. 4, 1999

Ontogen completes phase I study of MDR-modulating compound

Feb. 3, 1999

First NDA filing for Prevatac expected to be delayed

Feb. 2, 1999

Ilex Oncology adds Canadian trial site to intoplicine development

Feb. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...